Understanding DUPIXENT® for Eosinophilic Esophagitis
This observational study is for people with Eosinophilic Esophagitis (EoE), a condition where a type of white blood cell (eosinophil) builds up in the esophagus, causing inflammation and difficulty swallowing. It aims to learn more about how DUPIXENT® (dupilumab) is used in regular medical care for EoE. You can join if you are starting DUPIXENT® for EoE and are at least 1 year old. The study will track information like your age, race, and weight, and you'll complete questionnaires about how EoE affects your feelings, symptoms (like swallowing difficulty), and daily life over three years. The goal is to better understand EoE and help improve future treatments.
- Study design
- This is an observational study planning to include 350 participants. It does not involve new or experimental treatments; DUPIXENT® is prescribed as part of usual care.
- What's involved
- You will complete questionnaires about your EoE symptoms and quality of life. The study will track your demographic information and weight for up to 3 years after starting DUPIXENT®.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants' demographic characteristics, such as age, race, and weight, will be measured at the start of the study and for up to 3 years after beginning DUPIXENT® treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
At a glance
Conditions
Where it's being run
54 sites across 26 statesStudy leadership
- Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Demographic characteristic of participants who receive dupilumab for EoE: AgeBaseline and up to 3 years after treatment initiation
- Demographic characteristic of participants who receive dupilumab for EoE: RaceBaseline and up to 3 years after treatment initiation
- Demographic characteristic of participants who receive dupilumab for EoE: WeightBaseline and up to 3 years after treatment initiation
- Demographic characteristic of participants who receive dupilumab for EoE: HeightBaseline and up to 3 years after treatment initiation
- Disease characteristics of participants who receive dupilumab for EoE: Esophagogastroduodenoscopy (EGD)Baseline and up to 3 years after treatment initiation
- Disease characteristics of participants who receive dupilumab for EoE: Dilation/impaction historyBaseline and up to 3 years after treatment initiation
- Disease characteristics of participants who receive dupilumab for EoE: Dietary interventionsBaseline and up to 3 years after treatment initiation
- Disease characteristics of participants who receive dupilumab for EoE: Medical historyBaseline and up to 3 years after treatment initiation
- EoE medication history of participantPrevious 1 year and up to 3 years after treatment initiation
- Non-EoE medication history of participantPrevious 3 months and up to 3 years after treatment initiation
- Prior dupilumab exposure history of participantBaseline and up to 3 years after treatment initiation